As reported on Stock Titan, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Datroway® (datopotamab deruxtecan) as a…
Editor's Note: Patient Worthy is honored to share this story from our friends at Elephants & Tea, originally written by Amy Hoffmann — a survivor of triple-negative breast cancer. To…
Triple negative breast cancer, the most aggressive form of breast cancer, is under attack. Adelaide University researchers, led by Dr. Theresa Hinkey, report that unlike chemotherapy, the pill only targets…
Telomir Pharmaceuticals has taken a significant step forward in the development of a novel therapeutic agent for one of oncology's most challenging cancers. As reported by Pharmaceutical Technology, the company…
In the Phase 3 KEYNOTE-522 clinical trial, researchers found that pembrolizumab was effective in treating patients with triple-negative breast cancer (TNBC). According to Medical XPress, researchers wanted to determine whether…
Triple-negative breast cancer (TNBC), a rare and aggressive form of cancer, occurs when one's cancer is negative for progesterone receptors, estrogen receptors, and an excess of the HER2 protein. This…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
